Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
19
0
0
15
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 60/100
10.5%
2 terminated out of 19 trials
88.2%
+1.7% vs benchmark
0%
0 trials in Phase 3/4
7%
1 of 15 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 15 completed trials
Clinical Trials (19)
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma